These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 3730943)

  • 1. The contribution of alkylation to the activity of quinone antitumor agents.
    Begleiter A
    Can J Physiol Pharmacol; 1986 May; 64(5):581-5. PubMed ID: 3730943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of quinone alkylating agents in quinone-resistant cells.
    Begleiter A; Leith MK
    Cancer Res; 1990 May; 50(10):2872-6. PubMed ID: 1692249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the mechanism of action of quinone antitumor agents.
    Begleiter A
    Biochem Pharmacol; 1985 Aug; 34(15):2629-36. PubMed ID: 4015705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinone-induced DNA damage and its relationship to antitumor activity in L5178Y lymphoblasts.
    Begleiter A; Blair GW
    Cancer Res; 1984 Jan; 44(1):78-82. PubMed ID: 6537800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of L5178Y murine lymphoblasts resistant to quinone antitumor agents.
    Begleiter A; Leith MK; McClarty G; Beenken S; Goldenberg GJ; Wright JA
    Cancer Res; 1988 Apr; 48(7):1727-35. PubMed ID: 3127038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.
    Goldenberg GJ
    Cancer Res; 1975 Jul; 35(7):1687-92. PubMed ID: 1055634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytocidal action of the quinone group and its relationship to antitumor activity.
    Begleiter A
    Cancer Res; 1983 Feb; 43(2):481-4. PubMed ID: 6848172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms for the modulation of alkylating activity by the quinone group in quinone alkylating agents.
    Begleiter A; Leith MK; Pan SS
    Mol Pharmacol; 1991 Sep; 40(3):454-8. PubMed ID: 1896030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased sensitivity of quinone resistant cells to mitomycin C.
    Begleiter A; Robotham E; Lacey G; Leith MK
    Cancer Lett; 1989 Jun; 45(3):173-6. PubMed ID: 2471583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.
    Fourie J; Guziec F; Guziec L; Monterrosa C; Fiterman DJ; Begleiter A
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):191-203. PubMed ID: 14614574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mono and bis(bioreductive) alkylating agents: synthesis and antitumor activities in a B16 melanoma model.
    Witiak DT; Loper JT; Ananthan S; Almerico AM; Verhoef VL; Filppi JA
    J Med Chem; 1989 Jul; 32(7):1636-42. PubMed ID: 2738896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic mechanisms of anti-tumour quinones in parental and resistant lymphoblasts.
    Halinska A; Belej T; O'Brien PJ
    Br J Cancer Suppl; 1996 Jul; 27():S23-7. PubMed ID: 8763840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular pharmacology of quinone bioreductive alkylating agents.
    Rockwell S; Sartorelli AC; Tomasz M; Kennedy KA
    Cancer Metastasis Rev; 1993 Jun; 12(2):165-76. PubMed ID: 8375019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of cytosolic glutathione S-transferases in drug-resistant L5178Y murine lymphoblasts: chemical selectivity and molecular mechanisms.
    Stelmack GL; Goldenberg GJ
    Cancer Res; 1993 Aug; 53(15):3530-5. PubMed ID: 8101761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
    Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E
    Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the DNA-DNA cross-linking activity of 3'-(3-cyano-4-morpholinyl)-3'-deaminoadriamycin.
    Jesson MI; Johnston JB; Robotham E; Begleiter A
    Cancer Res; 1989 Dec; 49(24 Pt 1):7031-6. PubMed ID: 2531036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of trenimon-induced cytotoxicity in resistant L5178Y/HBM10 cells.
    Silva JM; O'Brien PJ
    Int J Radiat Oncol Biol Phys; 1992; 22(4):639-42. PubMed ID: 1371987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of resistance to DNA cross-linking agents in 9L cell lines with different sensitivities to chloroethylnitrosoureas.
    Bodell WJ; Gerosa M; Aida T; Berger MS; Rosenblum ML
    Cancer Res; 1985 Aug; 45(8):3460-4. PubMed ID: 3860285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
    Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-linking and sequence specific alkylation of DNA by aziridinyl quinones. 2. Structure requirements for sequence selectivity.
    Hargreaves RH; Mayalarp SP; Butler J; McAdam SR; O'Hare CC; Hartley JA
    J Med Chem; 1997 Jan; 40(3):357-61. PubMed ID: 9022802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.